BRPI0409867A - composição farmacêutica contendo lactato e usos da mesma - Google Patents

composição farmacêutica contendo lactato e usos da mesma

Info

Publication number
BRPI0409867A
BRPI0409867A BRPI0409867-6A BRPI0409867A BRPI0409867A BR PI0409867 A BRPI0409867 A BR PI0409867A BR PI0409867 A BRPI0409867 A BR PI0409867A BR PI0409867 A BRPI0409867 A BR PI0409867A
Authority
BR
Brazil
Prior art keywords
composition containing
pharmaceutical composition
per liter
lactate
millimoles per
Prior art date
Application number
BRPI0409867-6A
Other languages
English (en)
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of BRPI0409867A publication Critical patent/BRPI0409867A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Surgery (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA CONTENDO LACTATO E USOS DA MESMA". A presente invenção refere-se a uma composição farmacêutica contendo 250 a 2400 milimoles por litro de lactato ou ácido lático, 2 a 10 milimoles por litro de cátion de potássio e opcionalmente 2 a 5 milimoles por litro de cátion de cálcio. A presente invenção refere-se ainda aos usos farmacêuticos desta composição. A presente invenção refere-se também aos usos farmacêuticos de uma composição tendo uma concentração de ácido lático ou lactato entre 250 a 2400 milimoles por litro.
BRPI0409867-6A 2003-05-01 2004-03-22 composição farmacêutica contendo lactato e usos da mesma BRPI0409867A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01
PCT/SG2004/000066 WO2004096204A1 (en) 2003-05-01 2004-03-22 Lactate containing pharmaceutical composition and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0409867A true BRPI0409867A (pt) 2006-05-16

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409867-6A BRPI0409867A (pt) 2003-05-01 2004-03-22 composição farmacêutica contendo lactato e usos da mesma

Country Status (31)

Country Link
US (1) US20080125488A1 (pt)
EP (2) EP1759695A1 (pt)
JP (1) JP5037937B2 (pt)
KR (1) KR101076059B1 (pt)
CN (1) CN1777416B (pt)
AR (1) AR043670A1 (pt)
AT (1) ATE340568T1 (pt)
AU (1) AU2004233904B2 (pt)
BR (1) BRPI0409867A (pt)
CA (1) CA2523740C (pt)
CY (1) CY1105880T1 (pt)
DE (1) DE602004002585T2 (pt)
DK (1) DK1617834T3 (pt)
EA (2) EA013846B1 (pt)
ES (1) ES2274438T3 (pt)
HK (1) HK1085942A1 (pt)
IL (1) IL171721A (pt)
MA (1) MA27845A1 (pt)
MX (1) MXPA05011532A (pt)
MY (1) MY140382A (pt)
NO (1) NO20055652L (pt)
NZ (1) NZ543201A (pt)
PL (1) PL1617834T3 (pt)
PT (1) PT1617834E (pt)
SG (1) SG160217A1 (pt)
SI (1) SI1617834T1 (pt)
TN (1) TNSN05275A1 (pt)
TW (1) TWI290045B (pt)
UA (1) UA86937C2 (pt)
WO (1) WO2004096204A1 (pt)
ZA (1) ZA200509684B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285909A1 (en) * 2006-04-03 2009-11-19 Leverve Xavier M Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
DK2142186T3 (da) 2007-03-30 2014-08-04 Laccure Ab Anvendelse af oligomerer af mælkesyre ved behandling af gynækologiske infektioner
KR101639098B1 (ko) 2009-03-26 2016-07-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 폐 질환 치료용 건조 분말 제형 및 방법
CN102448439A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
EP2448571B1 (en) 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
DK3470057T3 (da) 2010-09-29 2021-11-22 Pulmatrix Operating Co Inc Kationiske tørpulvere omfattende magnesiumsalt
MX354828B (es) 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Polvos secos de cationes metálicos monovalentes para inhalación.
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
AU2013225982B2 (en) 2012-02-29 2017-11-30 Pulmatrix, Inc. Inhalable dry powders
EP2846787B1 (en) 2012-05-08 2018-08-29 Aeromics, Inc. Compounds for use in the treatment of aquaporin-mediated diseases
EP2879524B1 (en) * 2012-08-01 2016-09-07 Purac Biochem bv Lactate powder and method for the preparation thereof
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9808031B2 (en) 2012-10-25 2017-11-07 Run Them Sweet Llc Systems and methods to estimate nutritional needs of human and other patients
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
US9949991B2 (en) 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
CN109414036A (zh) 2016-07-07 2019-03-01 帝斯曼知识产权资产管理有限公司 获得油菜籽蛋白质分离物的方法以及由此获得的蛋白质分离物
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
WO2020163654A1 (en) * 2019-02-06 2020-08-13 Paul Leo Mcgrane Biologically modified vascular grafts for improved bypass surgery outcomes
EP4093507A4 (en) * 2020-01-24 2024-02-28 Daniel Q Barkey WEIGHT LOSS COMPOSITIONS AND METHODS
WO2023114375A2 (en) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6776887A (en) * 1985-12-18 1987-07-15 Veech, R.L. Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
AU681675B2 (en) * 1993-06-04 1997-09-04 Biotime, Inc. Plasma-like solution
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
SG160217A1 (en) 2010-04-29
SI1617834T1 (sl) 2007-02-28
AR043670A1 (es) 2005-08-03
CA2523740A1 (en) 2004-11-11
TWI290045B (en) 2007-11-21
US20080125488A1 (en) 2008-05-29
ES2274438T3 (es) 2007-05-16
NZ543201A (en) 2007-05-31
IL171721A (en) 2012-05-31
CN1777416A (zh) 2006-05-24
EA010948B1 (ru) 2008-12-30
EP1617834A1 (en) 2006-01-25
UA86937C2 (ru) 2009-06-10
JP5037937B2 (ja) 2012-10-03
DK1617834T3 (da) 2007-02-05
JP2006525324A (ja) 2006-11-09
MY140382A (en) 2009-12-31
MXPA05011532A (es) 2006-05-31
EP1617834B1 (en) 2006-09-27
EA200801073A1 (ru) 2008-08-29
KR101076059B1 (ko) 2011-10-21
NO20055652D0 (no) 2005-11-30
ZA200509684B (en) 2007-03-28
PL1617834T3 (pl) 2007-02-28
ATE340568T1 (de) 2006-10-15
CA2523740C (en) 2012-05-15
CN1777416B (zh) 2012-11-07
DE602004002585T2 (de) 2007-10-25
KR20050119701A (ko) 2005-12-21
NO20055652L (no) 2006-02-01
AU2004233904B2 (en) 2009-11-12
HK1085942A1 (en) 2006-09-08
EP1759695A1 (en) 2007-03-07
EA200501675A1 (ru) 2006-06-30
MA27845A1 (fr) 2006-04-03
AU2004233904A1 (en) 2004-11-11
CY1105880T1 (el) 2011-02-02
TNSN05275A1 (en) 2007-07-10
PT1617834E (pt) 2007-01-31
DE602004002585D1 (de) 2006-11-09
EA013846B1 (ru) 2010-08-30
WO2004096204A1 (en) 2004-11-11
TW200423923A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
BRPI0409867A (pt) composição farmacêutica contendo lactato e usos da mesma
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
BR0108734A (pt) Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas
MY145721A (en) Non-irritating compositions containing zinc salts
BRPI0510619A (pt) preparação e cápsula contendo a mesma
ES2570599T3 (es) Composición suave para desinfección cutánea
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR9801044A (pt) Composições antiácidas lìquidas.
PE20071038A1 (es) Procedimiento para la preparacion de ferrisuccinilcaseina
UA83328C2 (ru) Состав для профилактики заболеваний полости рта
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0012696A (pt) Composição oftálmica
AR060264A1 (es) Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion
BRPI0500594A (pt) Método de eletrodiálise, e, composição eletrodializada adequada para o consumo humano
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
BR9914644A (pt) Composições tamponadas para diálise
BRPI0519122A2 (pt) composiÇço oral, e, mÉtodo de reduzir o crescimento de placa bacteriana em uma cavidade oral de um indivÍduo
TW200715961A (en) Herbicide composition
BR0010150A (pt) Solução oral de prucalopride
ATE503394T1 (de) Naturmineralwasser zur prophylaxe, hygiene und behandlung von zahn- und zahnfleischerkrankungen
MY164917A (en) Lactate containing pharmaceutical composition and uses thereof
BR0104543A (pt) Bactéria fotossintética vermelha e alimento saudável
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
EA200400650A1 (ru) Трансдермальная фармацевтическая композиция, содержащая аспирин, для лечения кальцификации
PE20030732A1 (es) Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 33/00 (2006.01), A23L 33/16 (2016.01), A61K 3